Lupus & antiphospholipid syndrome

Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity

Lupus Sci MedPublished Cross-sectional study

Authors' conclusion

These results demonstrate a distinct clinical and serological SLE profile associated with components of the lectin pathway.

Study context

Population
Swedish patients with SLE and population-based matched controls
Participants
522 vs 322
Exposure
Highest vs lower quartiles of serum MAP-1 and MASP-2 concentrations in patients with SLE
  • SLEn = 522
  • Controlsn = 322reference
Outcome
Associations of highest-quartile serum MAP-1 with SLE manifestations and autoantibodies
Methodological detailscase-control, population-based matched controls, logistic regression, genetic association analysis
  • Case-control
  • Population-based matched controls
  • Logistic regression
  • Genetic association analysis

Main finding

As reported in the abstract

Discoid rash, MAP-1 highest quartile: OR
2.8 (95% CI 1.4 to 5.7)
Haematological manifestations, MAP-1 highest quartile: OR
2.1 (95% CI 1.1 to 3.7)
Autoantibodies against Sm, RNP, SSA and SSB, MAP-1 highest quartile: ORs 2.4 (95% CI 1.3 to 4.6) to 3.6
2.4 to 3.6 (95% CI 1.7 to 7.7)
Anti-β2GP1 and aCL IgG and IgA aPL, highest quartiles of MAP-1 and MASP-2 (lower rates): ORs 0.29 (95% CI 0.12 to 0.68) to 0.56
0.29 to 0.56 (95% CI 0.31 to 1.0)
Serum MAP-1 correlation with type I interferon activity, Spearman's rho (p<0.0001); interferon activity mediated MAP-1 associations with haematological manifestations and Sm/RNP autoantibodies
0.34

Observational data: associations, not effects.

Further findings

Protein quantitative trait loci for MAP-1 and MASP-2

Significant pQTLs identified; no consistent associations with SLE or specific SLE manifestations

Original publication

Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity. Lupus Sci Med. Published 9 April 2026. doi:10.1136/lupus-2025-001890

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.